טוען...
Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report
INTRODUCTION: sorafenib, a tyrosine-kinase inhibitor, is widely used in the treatment of advanced hepatocellular carcinoma. Drug-related toxicities are generally mild but sorafenib, as other similar agents, may induce elevation of systemic arterial blood pressure levels in relation to an interaction...
שמור ב:
Main Authors: | , , , , , , , , , |
---|---|
פורמט: | Artigo |
שפה: | Inglês |
יצא לאור: |
BioMed Central
2009
|
נושאים: | |
גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2803930/ https://ncbi.nlm.nih.gov/pubmed/20062650 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1757-1626-2-9133 |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|